OTS514

CAS No. 1338540-63-8

OTS514( OTS514 | OTS 514 | OTS-514 | OTS514 Hydrochloride )

Catalog No. M23492 CAS No. 1338540-63-8

OTS514 is a potent TOPK inhibitor. OTS514 exhibits a growth-suppressive effect on small cell lung cancer. OTS514 effectively suppressed the growth of SCLC cell lines (IC50: 0.4 ~ 42.6 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 155 In Stock
5MG 147 In Stock
10MG 235 In Stock
25MG 416 In Stock
50MG 550 In Stock
100MG 768 In Stock
200MG 1014 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    OTS514
  • Note
    Research use only, not for human use.
  • Brief Description
    OTS514 is a potent TOPK inhibitor. OTS514 exhibits a growth-suppressive effect on small cell lung cancer. OTS514 effectively suppressed the growth of SCLC cell lines (IC50: 0.4 ~ 42.6 nM).
  • Description
    OTS514 is a potent TOPK inhibitor. OTS514 exhibits a growth-suppressive effect on small cell lung cancer. OTS514 effectively suppressed the growth of SCLC cell lines (IC50: 0.4 ~ 42.6 nM). Treatment with OTS514 suppressed forkhead box protein M1 (FOXM1) activity. OTS514 treatment reduced CD90-positive SCLC cells and showed a higher cytotoxic effect against lung sphere-derived CSC-like SCLC cells.
  • In Vitro
    OTS514 (1.5625-100 nM) induces cell cycle arrest and apoptosis at nanomolar concentrations in a series of human myeloma cell lines (HMCL) and prevents outgrowth of a putative CD138+ stem cell population from multiple myeloma (MM) patient-derived peripheral blood mononuclear cells.Cell Viability Assay Cell Line:Human myeloma cell lines (MM1.S, MM1.R, RPMI 8226, 8226Dox40, KMS34, KMS34CFZ, KMS11, JJN3, LP-1, NCI H929, U266B1)Concentration:1.5625, 3.125, 6.25, 12.5, 25, 50, and 100 nM Incubation Time:72 hours Result:IC50 values ranged from 11.6 to 29.4 nM in parental cell lines, indicating a potent inhibitory effect. Only the RPMI 8226-Dox40 cell line, which overexpresses the multi-drug resistance transporter gene ABCB1, is resistant.
  • In Vivo
    OTS514 (1-5 mg/kg; once a day for 2 weeks; intravenous administration) induces tumor regression in a xenograft model of A549 cells (TOPK-positive lung cancer cells). Animal Model:Female BALB/cSLC-nu/nu mice bearing a xenograft model of A549 cells Dosage:1, 2.5, and 5 mg/kg Administration:Intravenously treated; once every day for 2 weeks Result:Resulted in tumor growth inhibition (TGI) of 5.7, 43.3, and 65.3% on day 15, respectively, without any body weight loss.
  • Synonyms
    OTS514 | OTS 514 | OTS-514 | OTS514 Hydrochloride
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    TOPK
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1338540-63-8
  • Formula Weight
    364.46
  • Molecular Formula
    C21H20N2O2S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:90 mg/mL?(246.94 mM;?Need ultrasonic)
  • SMILES
    CC(CN)c(cc1)ccc1-c(c(-c1c2scc1)c(c(C)c1)NC2=O)c1O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Ikeda Y, Park JH, Miyamoto T, Takamatsu N, Kato T, Iwasa A, Okabe S, Imai Y, Fujiwara K, Nakamura Y, Hasegawa K. T-LAK Cell-Originated Protein Kinase (TOPK) as a Prognostic Factor and a Potential Therapeutic Target in Ovarian Cancer. Clin Cancer Res. 2016 Dec 15;22(24):6110-6117. PubMed PMID: 27334838.
molnova catalog
related products
  • Naringenin-7-O-beta-...

    Naringenin-7-O-beta-D-glucuronide is a natural product.

  • Afloqualone

    Afloqualone is a agonist of GABA receptor . Target: GABA Receptor in vitro: Afloqualone is a quinazolinone family GABAergic drug. Afloqualone is an analogue of methaqualone.

  • Compound 35

    Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses.Compounds 35 are superior inhibitors of Ebola (Mayinga) and Marburg (Angola) infectious viruses. Compounds 35 have shown good metabolic stability in plasma and liver microsomes (rat and human), and 32 did not inhibit CYP3A4 nor CYP2C9.